Advanced

High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B Cell Lymphoma (DLBCL) Patients Treated with Dose Dense Chemoimmunotherapy and Systemic CNS Prophylaxis Results From a Nordic Phase II Study

Riihuarvi, Sari; Nyman, Heidi; Holte, Harald; Bjorkholm, Magnus; Fluge, Oystein; Pedersen, Lars Moller; Jerkeman, Mats LU ; Eriksson, Mikael LU and Leppa, Sirpa (2010) 52nd Annual Meeting of the American-Society-of-Hematology (ASH) In Blood 116(21). p.1686-1686
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Blood
volume
116
issue
21
pages
1686 - 1686
publisher
American Society of Hematology
conference name
52nd Annual Meeting of the American-Society-of-Hematology (ASH)
external identifiers
  • wos:000285025204561
ISSN
1528-0020
language
English
LU publication?
yes
id
e17554be-75c6-4343-aee3-a0be5553c143 (old id 1918001)
date added to LUP
2011-05-13 15:18:34
date last changed
2018-05-29 11:36:12
@misc{e17554be-75c6-4343-aee3-a0be5553c143,
  author       = {Riihuarvi, Sari and Nyman, Heidi and Holte, Harald and Bjorkholm, Magnus and Fluge, Oystein and Pedersen, Lars Moller and Jerkeman, Mats and Eriksson, Mikael and Leppa, Sirpa},
  issn         = {1528-0020},
  language     = {eng},
  note         = {Conference Abstract},
  number       = {21},
  pages        = {1686--1686},
  publisher    = {American Society of Hematology},
  series       = {Blood},
  title        = {High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B Cell Lymphoma (DLBCL) Patients Treated with Dose Dense Chemoimmunotherapy and Systemic CNS Prophylaxis Results From a Nordic Phase II Study},
  volume       = {116},
  year         = {2010},
}